Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors

American Journal of Pathology

Volumn 148, Issue 2, 1996, Pages 549-558

  Bacus, Sarah S ^a   Chin, Dot ^a   Yarden, Yosef ^b   Zelnick, Carolyn R ^a   Stern, David F ^c  

^a Advanced Cellular Diagnostics Inc   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; STEROID RECEPTOR;

ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; MOUSE; NEEDLE BIOPSY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TRANSGENIC ANIMAL;

BREAST NEOPLASMS; FEMALE; FROZEN SECTIONS; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; PHOSPHORYLATION; PHOSPHOTYROSINE; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0030043293     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. erbB4, a fourth member of the epidermal growth factor receptor family Proc Natl Acad Sci USA 1993, 90:1746-1750
2. neu/erbB-2 and the epidermal growth factor receptor Proc Natl Acad Sci USA 1992, 89:11637-11641
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987, 235:177-182
4. Hynes NE, Stern DF The biology of erbB-2/neu/HER-2 and its role in cancer Biochim Biophys Acta Rev Cancer 1994, 1198:165-184
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244: 707-712
6. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987, 6 605-610
7. Hollywood DP, Hurst HC A novel transcription factor, OB2-1, is required for overexpression of the protooncogene c-erbB-2 in mammary tumour lines EMBO J 1993, 12 2369-2375
8. HER2 causes transformation and tumorigenesis of NIH 3T3 cells Proc Natl Acad Sci USA 1987, 84.7159-7163
9. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J, Aaronson SA: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987, 51 1063-1070
10. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene Cell 1988, 54:105-115
11. Wang B, Kennan WS, Yasukawa-Barnes J, Lindstrom MJ, Gould MN. Difference in the response of neu and ras oncogene-induced rat mammary carcinomas to early and late ovariectomy Cancer Res 1992, 52: 4102-4105
12. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease Proc Natl Acad Sci USA 1992, 89:10578-10582
13. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. HER-2/neu amplification predicts poor survival in node-positive breast cancer Cancer Res 1990, 50.4332-4337
14. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh AR, Styles J, Rudenstam C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn H-J. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992, 10 1049-1056
15. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR Pathologic findings from the national surgical adjuvant breast and bowel project, prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990, 8.103-112
16. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994, 54: 2771-2777
17. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K, Folkman J: Betacellulin: a mitogen from pancreatic β cell tumors Science 1993, 259:1604-1607
18. Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, Todaro GJ, Shoyab M: The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 1990, 10:1969-1981
19. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF Science 251 936-939.
20. Toyoda H, Kornurasaki T, Uchida D, Takayama Y, Isobe T, Okuyama T, and Hanada K: Epiregulin. a novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 1995, 270: 7495-7500
21. neu. a potential model for receptor interactions EMBO J 1988, 7.995-1001
22. Goldman R, Ben Levy R, Peles E, Yarden Y: Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells a mechanism for receptor transregulation. Biochemistry 1990, 29:11024-11028
23. neu protein and EGF receptor modulates EGF receptor function Cell 1990, 61 1339-1347
24. erbB2. Science 1992, 256:1205-1210
25. Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Ben Levy R, Yarden Y. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells Cell 1992, 69: 205-216
26. Marchionni MA, Goodearl ADJ, Chen MS, Berminghan-McDonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kobayashi K, Wroblewski D, Lynch C, Baldassare M, Hiles I, Davis JB, Hsuan JJ, Totty NF, Otsu M, McBurney RN, Waterfield MD, Stroobant P, Gwynne D. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 1993, 362:312-318
27. Lupu R, Colomer R, Kannan B, Lippman ME Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci USA 1992, 89:2287-2291
28. Carraway KL III, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti AJ, Vandlen RL, Cantley LC, Cerione RA: The erbB3 gene product is a receptor for heregulin J Biol Chem 1994, 269 14303-14306
29. Kita YA, Barff H, Luo Y, Wen D, Brankow D, Hu S, Liu N, Prigent SA, Gullick WJ, Nicolson M NDF/herogulin stimulates the phosphorylation of Her3/erbB3 FEBS Lett 1994, 349:139-143
30. Plowman G, Green J, Culouscou J-M, Carlton G, Rothwell V, Buckley S. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 1993, 366. 473-475
31. Riese DJ II, Bermingham Y, van Raaij TM, Buckley S, Plowman GD, Stern DF: Betacellulin activates the epidermal growth factor receptor and erbB-4 and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β Oncogene 1996 (in press)
32. Riese DJ II, van Raaij TM, Plowman GD, Andrews GC, Stern DF: Cellular response to neuregulins is governed by complex interactions of the erbB receptor family Mol Cell Biol 1995, 15 5770-5776
33. neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2. Oncogene 1990, 5:879-883
34. Stern DF Antiphosphotyrosine antibodies in oncogene and receptor research. Methods Enzymol 1991, 198. 494-501
35. Lippman ME, Dickson RB: Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog Hormone Res 1989, 45.383-390
36. Epstein RJ, Druker BJ, Roberts TM, Stiles CD Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor. Proc Natl Acad Sci USA 1992, 89.10435-10439
37. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA 1991, 88:8691-8695
38. Bacus SS, Gudkov AV, Zeinick CR, Chin D, Stern R, Stancovski I, Peles E, Ben-Baruch N, Farbstein H, Lupu R, Wen D, Sela M, Yarden Y Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res 1993, 53.5251-5261
39. Bacus SS, Huberman E, Chin D, Kiguchi K, Simpson S, Lippman M, Lupu R: A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells Cell Growth Differ 1992, 3 401-411
40. Bacus SS, Ruby SG, Weinberg DS, Chin D, Ortiz R, Bacus JW HER-2/neu oncogene expression and proliferation in breast cancers. Am J Pathol 1990, 137: 103-111
41. Bacus S, Flowers JL, Press MF, Bacus JW, McCarty KS. The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Am J Clin Pathol 1988, 90.233-239
42. eu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res 1995, 55 1946-1955
43. Sainsbury JRC, Farndon JR, Harris AL, Sherbet GV. Epidermal growth factor receptors on human breast cancers Br J Surg 1985, 72.186-188
44. McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM: Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer 1992, 70.1775-1781
45. Elledge RM, McGuire WL, Osborne CK: Prognostic factors in breast cancer Semin Oncol 19:244-253
46. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991. 51:944-948
47. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS: Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 1983, 309. 1343-1347
48. Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Predicting response to endocrine therapy in human breast cancer a hypothesis. Science 1975, 189.726-727
49. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SAW, Killander D, McGuire WL. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990, 50:4332-4337
50. Topper YJ, Freeman CS: Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev 1980, 60:1049-1106
51. Russell KS, Hung M-C. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor Cancer Res 1992, 52:6624-6629
52. Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy Pharmacol Ther 1994, 64.127-154